MedTrace Logo

Ulcer Pomegranate Muffins

NCT07123259 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 82

Last updated 2025-08-19

No results posted yet for this study

Summary

Pomegranate (Punica granatum L.) peel powder, known for its potent antioxidant, anti-inflammatory, and antimicrobial properties, has shown promise in the dietary management of gastrointestinal disorders. In recent clinical observations, incorporating pomegranate peel powder into muffins consumed by patients with gastric ulcers demonstrated potential anti-ulcerative colitis activity. The bioactive compounds in the peel, such as polyphenols (punicalagins, ellagic acid), help reduce oxidative stress and modulate inflammatory pathways in the gut. Patients consuming these enriched muffins reported improvements in gastrointestinal symptoms, reduced mucosal inflammation, and enhanced mucosal healing, suggesting a supportive role of pomegranate peel as a functional food ingredient in managing gastric and colitis-related conditions.

Conditions

Interventions

DIETARY_SUPPLEMENT

WHOLE WHEAT MUFFIN

400g whole wheat flour was used for the development of muffins

COMBINATION_PRODUCT

1.5g enriched pomegranate muffins

1.5 g of pomegranate peel powder (PPP), alongside conventional medical therapy

COMBINATION_PRODUCT

3g enriched pomegranate muffins

3 g of pomegranate peel powder (PPP), alongside conventional medical therapy

Sponsors & Collaborators

  • University of Lahore

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-08-10
Primary Completion
2024-10-10
Completion
2024-10-12

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07123259 on ClinicalTrials.gov